{
    "Trade/Device Name(s)": [
        "PGDx elio tissue complete",
        "PGDx elio\u2122 tissue complete"
    ],
    "Submitter Information": "Personal Genome Diagnostics Inc.",
    "510(k) Number": "K192063",
    "Predicate Device Reference 510(k) Number(s)": [
        "DEN170058"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PZM"
    ],
    "Summary Letter Date": "July 31, 2019",
    "Summary Letter Received Date": "August 1, 2019",
    "Submission Date": "April 24, 2019",
    "Regulation Number(s)": [
        "21 CFR 866.6080"
    ],
    "Regulation Name(s)": [
        "Next generation sequencing based tumor profiling test"
    ],
    "Analyte Class(es)": [
        "cancer molecular",
        "genetic molecular",
        "anatomic pathology"
    ],
    "Analyte(s)": [
        "Somatic single nucleotide variants (SNVs)",
        "Insertions and deletions (indels)",
        "ERBB2 amplification",
        "Translocations: ALK, RET, NTRK2, NTRK3",
        "Microsatellite instability (MSI)",
        "Tumor mutation burden (TMB)",
        "505-gene panel (see gene list in document)"
    ],
    "Specimen Type(s)": [
        "Formalin-fixed, paraffin-embedded (FFPE) tumor tissue"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "NextSeq 550Dx (qualified by PGDx)"
    ],
    "Method(s)/Technology(ies)": [
        "Targeted next generation sequencing",
        "PCR",
        "Hybrid capture"
    ],
    "Methodologies": [
        "NGS variant detection",
        "Tumor profiling",
        "Hybrid capture sequencing"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent",
        "Software",
        "Platform",
        "Component"
    ],
    "Document Summary": "FDA 510(k) summary for PGDx elio tissue complete, a targeted NGS-based tumor profiling assay detecting SNVs, indels, amplifications, translocations, MSI and TMB from FFPE solid tumor tissue",
    "Indications for Use Summary": "Qualitative in vitro diagnostic for detecting tumor gene alterations, MSI, and TMB via targeted NGS of DNA from FFPE tissue of patients with solid malignant neoplasms; intended to aid tumor mutation profiling in previously diagnosed cancer patients",
    "fda_folder": "Pathology"
}